Author

Peng Cheng

Institution: Nanyang Medical College

Observed institution: Nanyang Medical College

ORCID: 0000-0001-9532-1306

Observed ORCID: 0000-0001-9532-1306

OpenAlex ID: A5101823675

A prognostic 3‐long noncoding RNA signature for patients with gastric cancer

2018 · Peng Cheng · Journal of Cellular Biochemistry · 61

Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study

2024 · Xiangrui Meng, Junsheng Wang, et al. · European Journal of Cancer · 26

Intravenous infusion (IV) or intracavitary perfusion (IP) of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody: Analyses of two phase 1 studies.

2024 · Jiaxin Niu, Minal A. Barve, et al. · Journal of Clinical Oncology · 3

Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.

2024 · Xiangrui Meng, Junsheng Wang, et al. · Journal of Clinical Oncology · 3

Thalidomide dose selection for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a multicenter, randomized phase II trial

2026 · Xiao Fu, Shuning Xu, et al. · Frontiers in Immunology

Early clinical diagnostic value of PGI, PGIIand G-17 in patients with atrophic gastritis and gastric cancer

2018 · Ping Guo, Xiaobing Chen, et al. · Central Plains Medical Journal

Works count: 6

Citation count: 93

H-index: 3

I10-index: 2